Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:34:54 EDT Mon 12 May 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

T:APLI - APPILI THERAPEUTICS INC. J - https://www.appilitherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
APLI - T  555.00.025·0.035157.00.0310.0030.03  0.03  0.030.05  0.02510:27:17May 0115 min RT 2¢
TSX - T555.00.025·0.035157.00.0310.0020.03  0.03  0.030.05  0.02510:27:1715 min
TriAct - M 0.030.0011    Sep 11/2015 min

Recent Trades - All 3 today
Time ETExPriceChangeVolumeBuyerSellerMarkers
15:42:57M0.03 180 National Bank80 National BankE
10:27:17T0.03 8,0007 TD Sec80 National BankK
10:27:17T0.03 2,00080 National Bank80 National BankKL
        
        
        
        
        
        
        

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2025-05-01 07:34C:APLI0.03News ReleaseAppili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
2025-04-28 17:47C:APLI0.03News ReleaseAppili Therapeutics granted patents in U.S., Mexico
2025-04-02 17:23C:APLI0.03News ReleaseAppili president to join Aditxt's April 4 update
2025-03-18 17:35C:APLI0.035News ReleaseAppili Therapeutics submits U.S. funding applications
2025-02-14 17:59C:APLI0.03SEDAR Interim MD & ASEDAR Interim MD & A
2025-02-14 17:53C:APLI0.03SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2025-02-14 17:06C:APLI0.03News ReleaseAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
2024-12-12 08:15C:APLI0.035News ReleaseAditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
2024-11-19 16:31C:APLI0.03News ReleaseAppili receives final court order for Aditxt deal
2024-11-14 08:35C:APLI0.035SEDAR Interim MD & ASEDAR Interim MD & A
2024-11-14 08:29C:APLI0.035SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-11-14 07:15C:APLI0.035News ReleaseAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
2024-11-08 08:30C:APLI0.04News ReleaseAditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
2024-11-07 08:30C:APLI0.035News ReleaseAditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
2024-11-06 18:20C:APLI0.035News ReleaseAppili shareholders approve Aditxt deal
2024-11-06 08:30C:APLI0.04News ReleaseAditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
2024-10-31 14:51C:APLI0.035News ReleaseAppili receives feedback from FDA for ATI-1801 plan
2024-10-31 08:30C:APLI0.035News ReleaseAditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
2024-10-30 17:35C:APLI0.035News ReleaseAppili Therapeutics to host conference call Nov. 1
2024-10-29 08:15C:APLI0.035News ReleaseSylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives